Inhibikase Therapeutics Inc (IKT)vsModerna Inc (MRNA)
IKT
Inhibikase Therapeutics Inc
$2.47
-0.80%
HEALTHCARE · Cap: $333.49M
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 222799999900% more annual revenue ($2.23B vs $1). IKT leads profitability with a 0.0% profit margin vs -141.4%. IKT earns a higher WallStSmart Score of 26/100 (F).
IKT
Avoid26
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IKT.
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IKT
The strongest argument for IKT centers on Altman Z-Score, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : IKT
The primary concerns for IKT are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
IKT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
IKT carries more volatility with a beta of 0.95 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
IKT generates stronger free cash flow (-12M), providing more financial flexibility.
Bottom Line
IKT scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Inhibikase Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?